A Phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier oncology group G05-92

Journal of Thoracic Oncology

Volumn 8, Issue 11, 2013, Pages 1425-1429

  Becerra, Carlos R ^a,b   Hanna, Nasser ^c   Mccollum, Andrew David ^a,b   Becharm, Naftali ^d   Timmerman, Robert D ^e   Dimaio, Michael ^e   Kesler, Kenneth A ^f   Yu, Menggang ^f   Yan, Tong ^f   Choy, Hak ^e  

^a US Oncology Research   (United States)

^b TEXAS ONCOLOGY   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Community Oncology Center ^*  (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Cetuximab; Esophageal; Radiation therapy; Resectable

Indexed keywords

CETUXIMAB;

ACNE; ACNEIFORM RASH; ADULT; AGED; ANOREXIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DEHYDRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; FATIGUE; FEMALE; GASTROESOPHAGEAL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERNATREMIA; INFECTION; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TREATMENT RESPONSE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; REMISSION INDUCTION;

EID: 84886586729     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182a46c3b     Document Type: Article

References (14)

1. Cancer Facts & Figures 2012. Atlanta, GA: American Cancer Society, 2012: No. 500812
2. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-467
3. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-1092
4. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992;326:1593-1598
5. Gibson MK, Abraham SC, Wu TT, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 2003;9:6461-6468
6. Pueyo G, Mesia R, Figueras A, et al. Cetuximab may inhibit tumor growth and angiogenesis induced by ionizing radiation: A preclinical rationale for maintenance treatment after radiotherapy. Oncologist 2010;15:976-986
7. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578
8. AJCC Cancer Staging Handbook, 6th Ed. New York, NY: Springer- Verlag, 2002
9. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Washington, DC: National Cancer Institute, 2006 Available at http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3. pdf Accessed March 9, 2011
10. Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys 2011;80:996-1001
11. Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity. Int J Radiat Oncol Biol Phys 2008;70:391-395
12. Ruhstaller T, Pless M, Dietrich D, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011;29:626-631
13. Leichman LP, Goldman BH, Bohanes PO, et al. S0356: A phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external- beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol 2011;29:4555-4560
14. Spigel DR, Greco FA, Meluch AA, et al. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2010;28:2213-2219